Biotech Bulls & Breakthroughs

→ WHAT IT COVERS Biotech trader Chef Station and BioPharm Catalyst's John Galliano review mid-2026 catalysts across 15+ small-cap biotech stocks, covering PDUFA dates from April through July, the FDA's new single-pivotal-trial approval standard, a psychedelics executive order signed April 18, and conference catalysts at AACR and ASCO. → KEY INSIGHTS - **FDA Single-Trial Approval Standard:** The FDA's February 2026 shift to accepting one statistically significant pivotal trial for...

→ WHAT IT COVERS Michael Heltzen, CEO of eXoZymes (Nasdaq), explains how his company manufactures complex natural compounds using cell-free enzymatic pathways combined with AI-driven protein engineering, with a lead product targeting metabolic health as both a nutraceutical and pharmaceutical candidate. → KEY INSIGHTS - **Cell-Free Manufacturing Advantage:** Traditional synthetic biology fails at scale because living cells actively resist overproduction, become toxic when pushed, and trap end...

→ WHAT IT COVERS Biotech trading analyst Shef and host John Galliano review the FDA's new single pivotal trial policy, its implications for small and mid-cap biotech companies, and catalog over fifteen specific catalyst opportunities across Q1 and Q2 2026, including PDUFA dates, phase data readouts, and conference presentations. → KEY INSIGHTS - **FDA One-Trial Policy:** The FDA's new default position, co-authored by Commissioner Martin Macri and CBER Director Vinay Prasad in a February 18 New...

→ WHAT IT COVERS Diagonal Therapeutics SVP Eric Duhaime explains how the 24-person private biotech uses clustering bispecific antibodies to target root-cause receptor mutations in rare genetic diseases, with lead program DIAC723 entering clinical trials in 2026 for HHT. → KEY INSIGHTS - **Root-cause targeting:** Diagonal's bispecific antibodies act as molecular glue, forcing four cell-surface receptors into a specific confirmation to restore normal intracellular signaling — directly fixing the...

→ WHAT IT COVERS Biotech trader Shev and BioPharm Catalyst's John Galliano review 18 small-cap biotech stocks across February–June 2026 catalysts, centering on how cash runway, institutional ownership, and float size determine risk-reward profiles for PDUFA dates, phase three readouts, and post-failed-trial recovery plays. → KEY INSIGHTS - **Cash Position as Risk Filter:** A company's cash runway determines downside severity when trials fail. Quince Pharmaceuticals (QNCX) fell from $3.25 to $0.

→ WHAT IT COVERS Biotech traders John Galliano and Chef Station analyze the JP Morgan Healthcare Conference 2026, covering two major acquisitions totaling $3.4 billion, the expanding role of AI in drug discovery, China's 33% share of medical innovations, and over a dozen specific PDUFA, IND, and clinical data catalysts expected in Q1 2026. → KEY INSIGHTS - **M&A Concentration Strategy:** Eli Lilly acquired Ventex Biosciences for $1.2 billion and GSK acquired Rap Therapeutics for $2.

→ WHAT IT COVERS Biotech trading veteran "Chef" and BioPharm Catalyst's John Galliano review 2025 biotech market conditions—including increased FDA transparency, reduced advisory committee requirements, and rising institutional investment—then preview 14 specific small-cap catalyst plays with near-term data readouts heading into JPMorgan 2026. → KEY INSIGHTS - **FDA Advisory Committee Reduction:** The FDA issued nearly zero advisory committee meetings for PDUFA reviews in 2025, a sharp...

→ WHAT IT COVERS Veteran biotech trader "Chef" reviews Q4 2025 catalyst plays with host John Galliano of BioPharma Catalyst, covering 15+ small-cap stocks with upcoming data readouts, PDUFA dates, and phase one trials, while analyzing what separates winning trades from losing ones as year-end approaches. → KEY INSIGHTS - **Catalyst Specificity:** Trades with defined dates—PDUFA deadlines, conference presentations, IND acceptance windows—outperform plays without fixed timelines.

→ WHAT IT COVERS MoMA Therapeutics VP of Corporate Development Neil Linebury outlines the company's NOMADIC platform for targeting dynamic proteins, explains two clinical-stage oncology programs focused on DNA repair pathways, and assesses the current biotech funding environment as moving from neutral toward cautious optimism. → KEY INSIGHTS - **DNA Polymerase Theta Inhibition:** MoMA's lead asset, MOMA-313, targets DNA polymerase theta to block a resistance mechanism that undermines PARP...

→ WHAT IT COVERS Biotech trader "Chef" and BioPharm Catalyst's John Galliano cover three macro themes — FDA rare disease policy shifts, Keytruda's August 2026 patent expiration, and ESMO 2025 previews — then walk through 20+ specific small-cap biotech catalysts spanning September through December 2025. → KEY INSIGHTS - **Rare Disease FDA Transparency:** The FDA's newly published five-year archive of Complete Response Letters lets investors identify exactly why drugs failed approval.

→ WHAT IT COVERS Veteran biotech trader Chef Station and BioPharm Catalyst's John Galliano review August 2025 market conditions, dissect Viking Therapeutics' oral obesity drug failure, and walk through 15+ specific small-to-mid-cap catalyst plays across August and September 2025, covering PDUFA dates, IND acceptances, NDA submissions, and phase trial data readouts.

→ WHAT IT COVERS BioSpace Senior Editor Annalee Armstrong joins Biotech Bulls & Breakthroughs on July 30, 2025 to assess the biopharma landscape, covering neurodegenerative disease pipelines, GLP-1 drug safety gaps, FDA regulatory instability under the Trump administration, PDUFA date delays, and AI-aided drug discovery's unproven track record. → KEY INSIGHTS - **Neurodegenerative pipeline opportunity:** Alzheimer's drug development is undervalued relative to its activity level.

→ WHAT IT COVERS Biotech trader Chef Station and BioPharma Catalyst's John Galliano walk through a systematic process for trading small-cap biotech stocks, covering how to identify catalysts using PDUFA dates, conference presentations, and FDA inspection records, followed by a July–August 2025 watch list of roughly 15 tickers across sleep apnea, oncology, and rare disease spaces.